Navigation Links
Positron Announces Reverse Stock Split and Registration as a Delaware Corporation
Date:9/23/2013

CHICAGO, Sept. 23, 2013 /PRNewswire/ -- Positron Corporation (OTCBB:POSC) (the "Company"), a nuclear medicine healthcare company specializing in the business of cardiac PET, announced today that it had filed a Preliminary Information Statement with the Securities and Exchange Commission ("SEC") to effect a one (1) for one hundred (100) reverse split of its issued and outstanding common shares (the: "Reverse Split").  The Company considers this action as the next step in a program to strengthen the Company's finances, market acceptance and marketability to the financial community and investing public.  Additionally, the Company intends to change its corporate domicile to the State of Delaware.

The Company intends to effect the Reverse Split pursuant to an amendment to its Certificate of Formation which was approved by written consent of the Company's Board of Directors and a Majority of the outstanding, voting capital stock. In the same filing, the Company intends to decrease the authorized number of common shares from 3,000,000,000 to 500,000,000 and amend the number of authorized shares of preferred stock to 20,000,000. All series of preferred shares will be adjusted on an equal basis in accordance with the Reverse Split.  The foregoing corporate actions were taken via majority consent of the stockholders and all appropriate notifications were filed and transmitted.

Upon effectiveness of the Reverse Split, each 100 shares of issued and outstanding common stock will be converted into 1 share of common stock. In addition, the Company's common stock will trade under a new CUSIP number. The Company's ticker symbol will remain unchanged, although a "D" will be placed on the ticker symbol, POSC, for 20 business days to alert the public of the Reverse Split. The Company anticipates that it will file the amendment in approximately thirty (30) days and that the Reverse Split will become approved shortly thereafter.

Many institutional investors and brokerage houses have internal practices and policies prohibiting holdings of lower-priced stocks in investment portfolios, which reduce the number of potential buyers of Common Stocks.  Additionally, analysts at many brokerage firms are reluctant to monitor the activity of lower-priced stocks or recommend lower-priced stocks to their clients.  Positron's Board of Directors believes that due to these policies and practices lower-priced stocks have become "off limit" or unattractive to brokers and the investing public.  It is for such reasons that this Reverse Split was deemed prudent and in the shareholders' best interest. Positron will also domicile the Company in Delaware, as it is a more favorable corporate governance jurisdiction and well recognized in the business community.

"Today Positron is a more accomplished and fundamentally stronger company than ever before," said Patrick G. Rooney, Chief Executive Officer of Positron. "We believe that our vertically integrated approach to the cardiac PET market is critical to the growth of the industry.  This integration provides strength and autonomy that will enable Positron to offer a continuous and complete end-to-end solution for cardiologists and their patients. The reverse stock split is simply a reclassification that we believe provides a more clear and manageable representation of our capitalization. This reclassification is an important step as we prepare to execute the next phase of our business plan in becoming an independent manufacturer of radioisotopes, providing a diversified portfolio of products related to key radiopharmaceuticals."

The Reverse Split will not require shareholders of the Company to exchange their existing stock certificates for new stock certificates, although, shareholders may do so if they wish. Please direct any questions you may have concerning the Reverse Split to your broker or the Company directly at investor@positron.com.

About Positron:

Positron Corporation is a nuclear medicine healthcare company vertically integrating all the segments of nuclear cardiology, providing an end-to-end solution for cardiac PET.  Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron's unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology.  Positron is redefining the industry.  More information about Positron is available at www.positron.com.

Forward Looking Statements:  Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Positron Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Positron Consolidates Radiopharmaceutical & Radioisotope Facilities
2. Positrons Attrius PET Scanner Now Utilized In Alzheimers Imaging With Amyvid Agent
3. Neusoft Positron Medical Systems Receives ISO Certification and CE Mark for their Attrius PET System
4. Positron Appoints Charles Conroy As Chief Operating Officer
5. Positron Introduces Next Generation PosiRx Pharmacy Automation Systems
6. Positron And Biologics Modular Enter Into Co-Marketing Agreement
7. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
8. Positron Retains Investment Banking Firm Covington Associates To Lead Financing Of Cyclotron Project
9. Positron And iThemba LABS Enters Into Radioisotope Supply Agreement
10. Piramal Imaging Provides Comments in Response to the Centers for Medicare and Medicaid Services (CMS) Proposed Coverage Decision for Beta-Amyloid Positron Emission Tomography (PET)
11. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
Breaking Medicine News(10 mins):